相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients
Axel Muendlein et al.
SCIENTIFIC REPORTS (2021)
MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
Angeliki Andrikopoulou et al.
CANCERS (2021)
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial
George W. Sledge et al.
JAMA ONCOLOGY (2020)
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer
Sara A. Hurvitz et al.
CLINICAL CANCER RESEARCH (2020)
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Carlotta Costa et al.
CANCER DISCOVERY (2020)
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial
Amelia McCartney et al.
CLINICAL CANCER RESEARCH (2020)
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
Robert H. Jones et al.
LANCET ONCOLOGY (2020)
Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials.
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.
Antonio Llombart-Cussac et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial.
Francois Clement Bidard et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Jing Xi et al.
CURRENT ONCOLOGY REPORTS (2020)
The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
Seth A. Wander et al.
CANCER DISCOVERY (2020)
Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer
Pingping Mao et al.
CLINICAL CANCER RESEARCH (2020)
Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows
Patrick J. Roberts et al.
MOLECULAR CANCER THERAPEUTICS (2020)
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma (vol 37, 340-353.e1-e6, 2020)
Beatriz Salvador-Barbero et al.
CANCER CELL (2020)
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer
Nicole M. Kettner et al.
CLINICAL CANCER RESEARCH (2019)
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Nicholas C. Turner et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer
Erik S. Knudsen et al.
ONCOGENE (2019)
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
Luigi Formisano et al.
NATURE COMMUNICATIONS (2019)
MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance
Liam Cornell et al.
CELL REPORTS (2019)
RB constrains lineage fidelity and multiple stages of tumour progression and metastasis
David M. Walter et al.
NATURE (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial
Antoinette R. Tan et al.
LANCET ONCOLOGY (2019)
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
Anna E. Vilgelm et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Breast cancer
Nadia Harbeck et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
Sarah Croessmann et al.
CLINICAL CANCER RESEARCH (2019)
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Kamal Pandey et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies
Utthara Nayar et al.
NATURE GENETICS (2019)
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene
Xueqian Gong et al.
CANCER DISCOVERY (2019)
Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
Matthew G. Oser et al.
CANCER DISCOVERY (2019)
To Cycle or Fight-CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity
Malaka Ameratunga et al.
CLINICAL CANCER RESEARCH (2019)
Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance
Jinfang Zhang et al.
NATURE (2018)
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Jiehui Deng et al.
CANCER DISCOVERY (2018)
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
G. N. Hortobagyi et al.
ANNALS OF ONCOLOGY (2018)
Abstract P4-03-05: AP-1 as a potential mediator of resistance to the cyclin-dependent kinase (CDK) 4/6-inhibitor palbociclib in ER-positive endocrine-resistant breast cancer
C De Angelis et al.
CANCER RESEARCH (2018)
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3
Dennis J. Slamon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
Claudia Allemani et al.
LANCET (2018)
ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment
Hetal Patel et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Preclinical Activity of Abemaciclib Alone or in Combination with Antimitotic and Targeted Therapies in Breast Cancer
Neil O'Brien et al.
MOLECULAR CANCER THERAPEUTICS (2018)
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
David A. Schaer et al.
CELL REPORTS (2018)
Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies
Joseph A. Caruso et al.
CANCER RESEARCH (2018)
First-line ribociclib (RIB) plus letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses
Gabriel N. Hortobagyi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
Ben O'Leary et al.
CANCER DISCOVERY (2018)
Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Zhiqiang Li et al.
CANCER CELL (2018)
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon et al.
CELL (2018)
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
R. Condorelli et al.
ANNALS OF ONCOLOGY (2018)
Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
Kelly K. Hunt et al.
CLINICAL CANCER RESEARCH (2017)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
CDK4/6 inhibition triggers anti-tumour immunity
Shom Goel et al.
NATURE (2017)
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
Smruthi Vijayaraghavan et al.
NATURE COMMUNICATIONS (2017)
Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD)
Changde Zhang et al.
ONCOTARGET (2017)
Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib
Xueqian Gong et al.
CANCER CELL (2017)
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Iman Doostan et al.
CLINICAL CANCER RESEARCH (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer
Cynthia X. Ma et al.
CLINICAL CANCER RESEARCH (2017)
Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Elizabeth K. Ziemke et al.
CLINICAL CANCER RESEARCH (2016)
Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer
Cansu Karakas et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
Maria Teresa Herrera-Abreu et al.
CANCER RESEARCH (2016)
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer
Charlotte Fribbens et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt
Jinfang Zhang et al.
MOLECULAR CELL (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models
Michael S. Lee et al.
ONCOTARGET (2016)
A gene expression signature of Retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer
Luca Malorni et al.
ONCOTARGET (2016)
Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities
Jorge Franco et al.
CELL REPORTS (2016)
Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer
Suzanne E. Wardell et al.
CLINICAL CANCER RESEARCH (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer
Nicholas C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
Marta Kovatcheva et al.
ONCOTARGET (2015)
Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer
L. M. Arthur et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Hbo1 Is a Cyclin E/CDK2 Substrate That Enriches Breast Cancer Stem-like Cells
MyLinh T. Duong et al.
CANCER RESEARCH (2013)
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
Patrick J. Roberts et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2012)
LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients
MyLinh T. Duong et al.
PLOS GENETICS (2012)
Cdk2 is Required for Breast Cancer Mediated by the Low-Molecular-Weight Isoform of Cyclin E
Said Akli et al.
CANCER RESEARCH (2011)
The meaning of p16ink4a expression in tumors Functional significance, clinical associations and future developments
Agnieszka K. Witkiewicz et al.
CELL CYCLE (2011)
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
Chellappagounder Thangavel et al.
ENDOCRINE-RELATED CANCER (2011)
ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
Todd W. Miller et al.
CANCER DISCOVERY (2011)
Cyclin E Deregulation Impairs Mitotic Progression through Premature Activation of Cdc25C
Rozita Bagheri-Yarmand et al.
CANCER RESEARCH (2010)
Low Molecular Weight Cyclin E Overexpression Shortens Mitosis, Leading to Chromosome Missegregation and Centrosome Amplification
Rozita Bagheri-Yarmand et al.
CANCER RESEARCH (2010)
Effects of 17β-Estradiol on Preadipocyte Proliferation in Human Adipose Tissue: Involvement of IGF1-R Signaling
E. Dos Santos et al.
HORMONE AND METABOLIC RESEARCH (2010)
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
J. L. Dean et al.
ONCOGENE (2010)
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
W. Ruprecht Wiedemeyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Cell cycle, CDKs and cancer: a changing paradigm
Marcos Malumbres et al.
NATURE REVIEWS CANCER (2009)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Tailoring to RB: tumour suppressor status and therapeutic response
Erik S. Knudsen et al.
NATURE REVIEWS CANCER (2008)
分享论文
